Search
terfenadine (Seldane)
Tradename: Seldane. FDA approved in 1985. Withdrawn from US market in 1998 [3].
Contraindications: Caution: do not use with liver failure
Dosage: 60 mg PO BID. 60 mg.
Adverse effects:
- QT-prolongation
Drug interactions:
1) erythromycin
2) ketoconazole
Pharmacokinetics:
- Fexofenadine is active metabolite
Interactions
drug adverse effects of H1 receptor antagonists
General
H1 receptor antagonist (antihistamine)
piperidine
Properties
MISC-INFO: elimination route LIVER
KIDNEY
pregnancy-category C
safety in lactation -
Database Correlations
PUBCHEM cid=5405
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed)
Lippincott-Raven, Philadelphia, 1998, pg 34
- Fresno Bee, Dec. 2000